Role of amylin in insulin secretion and action in humans: Antagonist studies across the spectrum of insulin sensitivity

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 2, 2002, Pages 118-126

  Mather, Kieren J ^a   Paradisi, Giancarlo ^a   Leaming, Rosalind ^a   Hook, Ginger ^a   Steinberg, Helmut O ^a   Fineberg, Naomi ^a   Hanley, Rochelle ^b   Baron, Alain D ^c,d  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Glucose disposal rate; Hyperglycemic clamp; Insulin resistance; Insulin sensitivity

Indexed keywords

AMYLIN; C PEPTIDE; GLUCOSE; HORMONE ANTAGONIST; INSULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AMYLOID; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; MALE; OBESITY; RECEPTORS, PEPTIDE; REFERENCE VALUES;

EID: 0036250177     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.263     Document Type: Article

References (57)

1. Amylin concentrations and glucose control
2. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas
3. Purification and characterization of amyloid-rich pancreases of Type 2 diabetic patients
4. Co-localization of islet amyloid polypeptide and insulin in the β-cell secretory granules of the human pancreatic islets
5. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin
6. Amylin/insulin secretory ratios in morbidly obese man: Inverse relationship with glucose disappearance rate
7. Decrease of stimulated amylin release precedes impairment of insulin secretion in Type II diabetes
8. Amylin compared with calcitonin gene-related peptide: Structure, biology, and relevance to metabolic disease
9. Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perfused rat islets
10. 8-37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats
11. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas
12. Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas
13. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output
14. Inhibition of glucose-induced secretion by amylin in rats in vivo
15. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas
16. Islet amyloid polypeptide (IAPP; Amylin) influences the endocrine but not the exocrine rat pancreas
17. Amylin and insulin in rat soleus muscle: Dose responses for cosecreted noncompetitive antagonists
18. Activation of PKa by amylin in skeletal muscle
19. Lack of islet amyloid polypeptide regulation of insulin biosynthesis or secretion in normal rat islets
20. The effect of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat pancreatic islets in vitro
21. Effects of islet amyloid polypeptide (IAPP) on insulin biosynthesis or secretion in rat islets and mouse BTC3 cells. Biosynthesis of IAPP in mouse BTC3 cells
22. Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets
23. Amylin and amylin-amide lack an acute effect on blood glucose and insulin
24. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets
25. Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion
26. Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system
27. Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity
28. High affinity amylin binding sites in rat brain
29. Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells
30. Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists
31. 8-37h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo
32. Antagonistic effect of human alpha-calcitonin gene-related peptide (8-37) on regional hemodynamic actions of rat islet amyloid polypeptide in conscious Long-Evans rats
33. Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: Study in the perfused pancreas of the rat
34. Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets
35. Receptors for calcitonin gene-related peptide (CGRP) on insulinoma membranes
36. Direct interaction of islet amyloid polypeptide (IAPP) with calcitonin gene-related peptide (CGRP) receptor present in B cell membrane
37. Amylin and insulin in rat soleus muscle: Dose responses for co-secreted non-competitive antagonists
38. Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved
39. Characterization of receptors for calcitonin gene-related peptide and adrenomedullin on the guinea-pig vas deferens
40. Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats
41. Non-steady state: Error analysis of Steele's model and developments for glucose kinetics
42. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance
43. Animal calorimetry: An analysis of the oxidation of mixture of carbohydrate and fat
44. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma
45. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients
46. Prehepatic insulin production in man: Kinetic analysis using peripheral connecting peptide behavior
47. Validation of methods for measurement of insulin secretion in humans in vivo
48. Amylin compared with calcitonin gene-related peptide: Structure, biology, and relevance to metabolic disease
49. Molecular physiology of amylin
50. Amylin regulation of fuel metabolism
51. Newly identified pancreatic protein islet amyloid polypeptide: What is its relationship to diabetes?
52. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinemic euglycemic clamp in humans
53. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment
54. Role of islet amyloid polypeptide secretion in insulin-resistant humans
55. Is islet amyloid polypeptide a significant factor in pathogenesis or pathophysiology of diabetes?
56. Amylin found in amyloid deposits in human Type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle
57. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro